Pharmaceutical and diagnostic business systems and methods
Improved pharmaceutical and diagnostic business systems and methods are disclosed. One or more genomes are scanned for single nucleotide polymorphisms. The polymorphisms are assigned to haplotype blocks, and representative SNPs from the haplotype blocks are used in association studies for pharmaceutical and diagnostic development.
1. The business method comprising:
a. identifying genetic variations in a plurality of individuals comprising scanning more than 10,000,000 bases;
b. identifying at least one of said genetic variations that is genetically linked with at least one other of said genetic variations; and
c. collaborating with a partner to correlate said one of said genetic variations that is genetically linked with at least one other of said genetic variations with a phenotypic state.
2. The business method of claim 1 , wherein said genetic variations are single nucleotide polymorphisms.
3. The business method of claim 1 wherein said genetic variations occur in more than 2% of said individuals.
4. The business method of claim 1 wherein said plurality of individuals is comprised of individuals from a set of different ethnic groups.
5. The business method of claim 1 wherein said phenotypic state is selected from the group consisting of adverse drug response, positive drug response, no drug response, ameliorated drug response in one patient as compared to another patient, and reduced drug response in one patient as compared to another patient.
6. The business method of claim 1 wherein said partner funds said collaboration step.
7. The business method of claim 1 further comprising the step of using results from the collaborating step to stratify patients.
8. The business method of claim 1 further comprising the step of using the results from the collaborating step to generate diagnostics.